Ectylurea

Ectylurea

SCHEMBL1641674

C/C=C(\CC)C(=O)NC(N)=O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.39
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ectylurea SCHEMBL1641676 1.00 CRBN (0.39) CRBNMAPTRAB9ANPSR1
Ectylurea SCHEMBL8189887 1.00 CRBN (0.39) CRBNMAPTRAB9ANPSR1
SCHEMBL20317510 0.76 ALDH1A1 (0.32)
SCHEMBL29415851 0.74 CRBN (0.31) CRBN
SCHEMBL19011343 0.73
SCHEMBL28716275 0.73
SCHEMBL27460647 0.73 CRBN (0.43) CRBNMAPTRAB9ANPSR1
SCHEMBL11372614 0.72
SCHEMBL4742487 0.72
SCHEMBL28719312 0.71 MMP1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180119119-A1 DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS BY BACTERIAL INJECTION OF TALEN PROTEINS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2018-05-03 US claimed
US-9770514-B2 Tamper-resistant pharmaceutical dosage forms ExxPharma Therapeutics LLC (US) 2017-09-26 US claimed
WO-2016168709-A1 DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS BY BACTERIAL INJECTION OF TALEN PROTEINS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-10-20 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20150064250-A1 Tamper-Resistant Pharmaceutical Dosage Forms ExxPharma Therapeutics LLC (US) 2015-03-05 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20040167358-A1 Method and reagents for N-alkylating ureides GUTMAN DANIELA (IL) 2004-08-26 US claimed
EP-1027339-B1 METHOD AND REAGENTS FOR N-ALKYLATING UREIDES TARO PHARMA IND (IL) 2004-01-02 EP claimed
US-20030018080-A1 N-methoxymethyl-5,5-diphenylbarbituric acid TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-01-23 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-1027339-A1 METHOD AND REAGENTS FOR N-ALKYLATING UREIDES TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) 2000-08-16 EP claimed
US-6093820-A REACTING AN IMIDE WITH A (SUBSTITUTED)ALKOXYALKYLSULFONIC ACID ESTER TO FORM A N-ALKOXYALKYL IMIDE SUCH AS METHOXYMETHYL ETHOSUXIMIDE; ADMINISTERING AS ANTICONVULSANT, ANTIANXIETY AGENT AND MUSCLE RELAXANT TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2000-07-25 US claimed
WO-1999018084-A1 METHOD AND REAGENTS FOR N-ALKYLATING UREIDES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 1999-04-15 WO claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018080-A1 N-methoxymethyl-5,5-diphenylbarbituric acid MGMT, ALKBH3, ALKBH5 CRBN 2070/4885MAPT 3277/4885RAB9A 4198/4885
US-20040167358-A1 Method and reagents for N-alkylating ureides MGMT, ETV6, ALKBH3 CRBN 1168/4885MAPT 3104/4885RAB9A 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.